These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

115 related items for PubMed ID: 7184383

  • 21. Intraperitoneal administration of the biological response modifier OK-432 and peritoneal recurrence following gastrectomy.
    Tsujitani S, Abe Y, Korenaga D, Saitoh A, Watanabe A, Sugimachi K.
    Hepatogastroenterology; 1990 Oct; 37(5):498-502. PubMed ID: 2253926
    [Abstract] [Full Text] [Related]

  • 22. Therapeutic effect of OK-432 induced endogenous TNF on tumor bearing mice and cancer patients.
    Watanabe N, Niitsu Y, Yamauchi N, Neda H, Sone H, Urushizaki I, Yamamoto A, Nagamuta M, Sugawara Y.
    Immunopharmacol Immunotoxicol; 1988 Oct; 10(1):53-65. PubMed ID: 3361071
    [Abstract] [Full Text] [Related]

  • 23. [Immunological study on localized liver injection of immunopotentiator OK-432-- experimental studies in rats].
    Takada T, Yasuda H, Uchiyama K, Hasegawa H.
    Gan To Kagaku Ryoho; 1984 Oct; 11(10):2267-71. PubMed ID: 6333213
    [Abstract] [Full Text] [Related]

  • 24. [Correlation between anti-tumor effect and delayed hypersensitivity induced by topically applied OK-432 with histological findings].
    Kokunai I, Mori T, Yayoi E, Matuura N, Kosaki G.
    Nihon Geka Gakkai Zasshi; 1985 Mar; 86(3):258-65. PubMed ID: 3982380
    [Abstract] [Full Text] [Related]

  • 25. [Immunopotentiation by OK-432 ointment to apply to the mouse abdominal skin].
    Matsuoka H, Yano K, Baba H, Kounoe S, Seo Y, Saito T, Tomoda H, Wakasugi H.
    Gan To Kagaku Ryoho; 1995 Sep; 22(11):1644-6. PubMed ID: 7574783
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. [Effect of malignant ascitic fluids and OK-432 on the induction of LAK activity in peripheral blood mononuclear cells of gynecological cancer patients].
    Kanaoka Y, Umesaki N.
    Nihon Sanka Fujinka Gakkai Zasshi; 1991 Jun; 43(6):611-8. PubMed ID: 1856521
    [Abstract] [Full Text] [Related]

  • 33. [Combined effect of intraperitoneally administered OK-432 and recombinant interleukin (rIL-2) against mouse tumors].
    Fujioka T, Shiraishi M, Tanji S, Koike H, Kumagai K, Kubo T, Ohhori T.
    Nihon Gan Chiryo Gakkai Shi; 1989 May 20; 24(5):948-56. PubMed ID: 2789265
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. [Treatment of malignant ascites. II. Immunological studies on disappearance of ascites by intraperitoneal injection of a streptococcal preparation, OK-432 (author's transl)].
    Katano M.
    Fukuoka Igaku Zasshi; 1981 Oct 20; 72(10):543-55. PubMed ID: 7327499
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.